IQVIA

IQVIA is an American health information technology and clinical research company headquartered in Durham, North Carolina.^[2] The company provides healthcare data and analytics, technology solutions, contract research services, and commercial outsourcing to pharmaceutical, biotechnology, medical device, and healthcare organizations worldwide.^[1][2][6].

Listed on the New York Stock Exchange under the ticker IQV and a constituent of the S&P 500, IQVIA reported revenue of approximately US$16.3 billion in 2025 and employs around 93,000 people.^[2] It was formed through the 2016 merger of contract research organization Quintiles and healthcare data provider IMS Health, operating briefly as QuintilesIMS before adopting the IQVIA name in November 2017.^[3][4]

What It Does

IQVIA operates through three business segments. Technology & Analytics Solutions supplies healthcare data, analytics, and cloud software, including customer relationship management applications for life sciences companies. Research & Development Solutions functions as a contract research organization managing clinical trials from phase I through IV, including protocol design, site start-up, patient recruitment, monitoring, data management, and biostatistics. Contract Sales & Medical Solutions provides contract sales forces and patient engagement services.^[2]

Through its technology and analytics business the company maintains access to more than one billion anonymized patient records globally, which underpin market intelligence products used across the pharmaceutical industry.^[2]

Data and Methodology

The company's data assets trace to IMS Health's pharmaceutical sales auditing, historically built on wholesaler and pharmacy transaction data covering prescription drug movements, later extended with patient-level claims through acquisitions such as PharMetrics in 2005 and SDI Health in 2011.^[2]

As of its most recent annual reporting cited by Wikipedia, IQVIA describes access to roughly 1.2 billion unique non-identified patient records worldwide, combined with proprietary references on physicians, institutions, and product launches. Data is de-identified before use, an approach tested in litigation over physician prescribing data described below.^[2]

Products

Offerings span syndicated market measurement of global pharmaceutical sales, real-world evidence platforms, SaaS applications for commercial teams inherited from acquisitions such as Cegedim's CRM business and Incential sales performance management, analytics consulting, and clinical development services delivered as full-service outsourcing or functional service models.^[2]

The company also operates connected devices and decentralized trial capabilities, and has provided national health statistics infrastructure, including the United Kingdom Office for National Statistics' COVID-19 infection survey operations.^[2]

Delivery and Pricing

Products are delivered through enterprise subscriptions, licensed datasets, embedded service teams, and multi-year clinical outsourcing contracts. Research & Development Solutions generated about 55 percent of 2024 revenues, Technology & Analytics around 40 percent, and Contract Sales & Medical roughly 5 percent.^[2]

Pricing is negotiated contractually and not published; clinical programs are typically billed through fixed-fee or fee-for-service schedules, while data subscriptions are scoped by geography and therapeutic coverage.^[2]

Buyers and Use Cases

Customers are primarily pharmaceutical and biotechnology companies using IQVIA data for market sizing, brand performance tracking, forecasting, and real-world evidence generation, alongside hospitals, pharmacists, and payers using its analytics services.^[2]

Governments have contracted the company for population health surveillance, and regulators and investors rely on its published market estimates as reference figures for the global medicines market.^[2]

History

Dennis Gillings founded Quintiles in North Carolina in 1982, building it into the world's largest contract research organization after acquiring Innovex in 1996. Quintiles went public in 1997, was taken private in 2003, and returned to the New York Stock Exchange under ticker Q in May 2013 with an initial public offering that raised US$947 million.^[2][5]

IMS Health, originally Intercontinental Marketing Statistics, grew as the dominant auditor of pharmaceutical sales, spent years as part of the Dun & Bradstreet group before its 2000 spin-off, and was taken private in February 2010 by TPG Capital, the CPP Investment Board, and Leonard Green & Partners.^[2]

In May 2016 IMS Health agreed to merge with Quintiles in a deal valued at about US$9 billion; the merger completed that October, creating a US$17.6 billion company named QuintilesIMS.^[4] On November 6, 2017, the company adopted the name IQVIA, combining the initials of IMS Health and Quintiles with the Latin via.^[3]

In 2023 the Federal Trade Commission sued to block IQVIA's acquisition of advertising firm Propel Media, and a federal judge granted a preliminary injunction in December 2023; the companies abandoned the deal in January 2024.^[2] The company ranked 282nd on the Fortune 500 in its most recent listing cited by Wikipedia.^[2]